UBS’s Altimmune ALT Stock Holding History

UBS’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$36K	Sell	67 -91	-58%	-$47.6K	﹤0.01%	7219
2014 Q2	$67K	Sell	158 -4	-2%	-$1.81K	﹤0.01%	6464
2014 Q1	$89K	Buy	162 +12	+8%	+$7.01K	﹤0.01%	6128
2013 Q4	$83K	Buy	+150	New	+$89.5K	﹤0.01%	6288
2013 Q3	–	Sell	-60	Closed	-$34.4K	–	10314
2013 Q2	$29K	Buy	+60	New	+$29.8K	﹤0.01%	7413

Other funds holding ALT

PGCM

Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

OTPPB

Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Potomac Capital Management New York $115M AUM

GMCM

Gruber & McBaine Capital Management San Francisco, California $369M AUM 12.23% 1-Year Est. Return

Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return

UBS's ALT Position: Q3 2014 in Review

UBS reduced its Altimmune (ALT) stake by 58% in Q3 2014, selling an estimated $47.6K and leaving 67 shares worth $36K. The position accounts for ﹤0.01% of the portfolio, ranked #7219.

UBS first reported a position in ALT in Q2 2013 and has held it in 5 quarters since. The position peaked at $89K in Q1 2014. 37 funds tracked by Wall St. Rank hold ALT as of Q3 2014.

UBS held 67 shares of Altimmune worth $36K as of Q3 2014.
UBS sold 91 Altimmune shares in Q3 2014, an estimated $47.6K.
Altimmune made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7219 holding.
UBS first reported a position in Altimmune in Q2 2013 and has held it in 5 quarters since.
UBS's Altimmune position peaked at $89K in Q1 2014.
37 funds tracked by Wall St. Rank held Altimmune as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.